New forecasting technique 'set to move pharma to new areas'

It's set to turn business intelligence on its head. One senior pharma director of strategic planning has announced it 'will move pharma to new areas'. It's a new forecasting technology that's already been adopted by Novartis, GSK, Lilly, J&J and Pfizer. It's called 'A Prediction Market'.

There are three places you can find out more about Prediction Markets and pharma:

  • Free Exclusive Eyeforpharma Podcast which includes the highlights of a recent exclusive conference speech and an interview with the world academic expert all in just 10-minutes!
  • A Free White Paper on the subject, which includes a concise explanation, statistics and quotes
  • A highly informative live 1-hour online conference on Wednesday 5th September for only $99 if you book this week (reduced from $199). Learn from the experts - you'll hear 3 world class authorities addressing the subject.

More information and all 3 sources can be accessed at www.eyeforpharma.com/virtual/forecastingpm/

About EyeforPharma
EyeforPharma is a global pharmaceutical business strategy information provider with a highly reputable and worldwide presence in the pharma industry. It is renowned for producing top level conferences that attract the highest level of speakers to deliver presentations on cutting edge pharmaceutical business strategies. It provides business intelligence and analysis online at www.eyeforpharma.com. EyeforPharma also has a very strong foothold in the European, US and Japanese markets.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]